Bruno Sangro

Bruno Sangro

Universidad de Navarra - Pamplona / Spain
Others
AD Scientific Index ID: 4306961
University of Navarra
person_outline Bruno Sangro's MOST POPULAR ARTICLES
1-) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialAB El-Khoueiry, B Sangro, T Yau, TS Crocenzi, M Kudo, C Hsu, TY Kim, ...The Lancet 389 (10088), 2492-2502, 201731382017
2-) BCLC strategy for prognosis prediction and treatment recommendation: The 2022 updateM Reig, A Forner, J Rimola, J Ferrer-Fàbrega, M Burrel, Á Garcia-Criado, ...Journal of hepatology 76 (3), 681-693, 202223182022
3-) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—the ALBI gradePJ Johnson, S Berhane, C Kagebayashi, S Satomura, M Teng, ...Journal of Clinical Oncology 33 (6), 550-558, 201522992015
4-) Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trialT Yau, YK Kang, TY Kim, AB El-Khoueiry, A Santoro, B Sangro, I Melero, ...JAMA oncology 6 (11), e204564-e204564, 202010842020
5-) A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis CB Sangro, C Gomez-Martin, M de la Mata, M Iñarrairaegui, E Garralda, ...Journal of hepatology 59 (1), 81-88, 201310722013